BACKGROUND: The effectiveness of repetitive transcranial magnetic stimulation (TMS) is well established while studies of maintenance TMS are lacking. We aim here to determine whether maintenance is associated to a decrease in the relapse rate of depression, following successful acute treatment. METHODS: We enrolled 59 consecutive patients with pharmacoresistant depression who have responded (>50% decrease in symptom severity) up to 6 weeks of acute TMS treatment. These patients received either 20 weeks of maintenance TMS (n=37) or no additional TMS treatment (n=22). We performed propensity adjusted-analysis to examine the association between the relapse rate over this 20-week period and maintenance TMS. Propensity analysis eliminated differences in baseline characteristics between patient with and without maintenance TMS and approximated the conditions of random site-of-treatment assignment. RESULTS: At 20 weeks, relapse rate was significantly different between the two groups (p=0.004, propensity analysis): 14 patients in the maintenance TMS group (37.8%) vs. 18 in the non-maintenance TMS group (81.8%), with an adjusted Hazard Ratio (HR)=0.288 (0.124-0.669). CONCLUSIONS: Maintenance TMS was associated with a significantly lower relapse rate in patients with pharmacoresistant depression in routine practice among responders.
BACKGROUND: The effectiveness of repetitive transcranial magnetic stimulation (TMS) is well established while studies of maintenance TMS are lacking. We aim here to determine whether maintenance is associated to a decrease in the relapse rate of depression, following successful acute treatment. METHODS: We enrolled 59 consecutive patients with pharmacoresistant depression who have responded (>50% decrease in symptom severity) up to 6 weeks of acute TMS treatment. These patients received either 20 weeks of maintenance TMS (n=37) or no additional TMS treatment (n=22). We performed propensity adjusted-analysis to examine the association between the relapse rate over this 20-week period and maintenance TMS. Propensity analysis eliminated differences in baseline characteristics between patient with and without maintenance TMS and approximated the conditions of random site-of-treatment assignment. RESULTS: At 20 weeks, relapse rate was significantly different between the two groups (p=0.004, propensity analysis): 14 patients in the maintenance TMS group (37.8%) vs. 18 in the non-maintenance TMS group (81.8%), with an adjusted Hazard Ratio (HR)=0.288 (0.124-0.669). CONCLUSIONS: Maintenance TMS was associated with a significantly lower relapse rate in patients with pharmacoresistant depression in routine practice among responders.
Authors: Roumen V Milev; Peter Giacobbe; Sidney H Kennedy; Daniel M Blumberger; Zafiris J Daskalakis; Jonathan Downar; Mandana Modirrousta; Simon Patry; Fidel Vila-Rodriguez; Raymond W Lam; Glenda M MacQueen; Sagar V Parikh; Arun V Ravindran Journal: Can J Psychiatry Date: 2016-08-02 Impact factor: 4.356
Authors: Michael S Kelly; Albino J Oliveira-Maia; Margo Bernstein; Adam P Stern; Daniel Z Press; Alvaro Pascual-Leone; Aaron D Boes Journal: J Neuropsychiatry Clin Neurosci Date: 2016-11-30 Impact factor: 2.198
Authors: Kyle P Fitzgibbon; Donna Plett; Brian C F Chan; Rebecca Hancock-Howard; Peter C Coyte; Daniel M Blumberger Journal: Can J Psychiatry Date: 2019-12-05 Impact factor: 4.356
Authors: Antal Zemplényi; Judit Józwiak-Hagymásy; Sándor Kovács; Dalma Erdősi; Imre Boncz; Tamás Tényi; Péter Osváth; Viktor Voros Journal: BMC Psychiatry Date: 2022-06-28 Impact factor: 4.144
Authors: Joseph J Taylor; John H Krystal; Deepak C D'Souza; Jason Lee Gerrard; Philip R Corlett Journal: Schizophr Res Date: 2017-09-29 Impact factor: 4.939